V2ACT Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Latest Deal Type
-
Joint Venture
- Financing Rounds
-
1
V2ACT Therapeutics General Information
Description
Operator of oncology drug discovery company intended to serve the healthcare sector. The company develops and commercializes a product candidate, V2ACT Immunotherapy, that combines an oncolytic virus and neoantigen-primed adoptive cell therapy (NACT) for cancer.
Contact Information
Corporate Office
- 3030 Bunker Hill Street
- Suite 310
- San Diego, CA 92109
- United States
Corporate Office
- 3030 Bunker Hill Street
- Suite 310
- San Diego, CA 92109
- United States
V2ACT Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
V2ACT Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
V2ACT Therapeutics FAQs
-
When was V2ACT Therapeutics founded?
V2ACT Therapeutics was founded in 2019.
-
Where is V2ACT Therapeutics headquartered?
V2ACT Therapeutics is headquartered in San Diego, CA.
-
What industry is V2ACT Therapeutics in?
V2ACT Therapeutics’s primary industry is Drug Discovery.
-
Is V2ACT Therapeutics a private or public company?
V2ACT Therapeutics is a Private company.
-
What is V2ACT Therapeutics’s current revenue?
The current revenue for V2ACT Therapeutics is .
-
Who are V2ACT Therapeutics’s investors?
Genelux and TVAX Biomedical have invested in V2ACT Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process